Hunters Consider Lyme Disease Vaccine Amid Tick Season Challenges

Matthew Mealer showcased his targets at the Busch Shooting Range in Weldon Spring, Missouri, in May. Despite his skepticism towards new vaccines, Mealer expressed willingness to consider a Lyme disease vaccine if deemed safe and effective.

Tick season poses significant challenges, potentially the most severe in a decade. Climate change is expanding habitats suitable for tick survival, increasing the exposure of Americans to tick-related health issues. These include Rocky Mountain spotted fever, alpha-gal triggered meat allergies, and the prevalent Lyme disease.

Vaccine Developments

Pharmaceutical giants Pfizer and Valneva announced plans to seek regulatory approval for a Lyme disease vaccine this spring. The previous Lyme vaccine available in the late 1990s faced challenges such as lawsuits, side effect fears, and limited interest—resulting in its withdrawal within three years. Current times, marked by vaccine skepticism post-COVID, may influence the reception of this new vaccine.

Perspectives from the Woods

Members of the hunting community, who often spend long hours in tick-infested woods, might be pivotal in gauging potential vaccine success. Hunters, typically conservative, rural, and male according to surveys by the Theodore Roosevelt Conservation Partnership, show increased vaccine hesitancy. Ashley Kirzinger, associate director for Public Opinion at KFF, highlights these demographic traits.

Jess Manganelli, a hunter at Busch Shooting Range, expressed openness to the vaccine due to frequent outdoor exposure. Despite not receiving formal Lyme diagnosis, Manganelli recounted tick bite aftermath involving muscle weakness and fatigue.

The Impact of Lyme Disease

According to the CDC, untreated Lyme disease can progress from fever and headaches to serious symptoms like arthritis and inflammation of the brain. An estimated 476,000 cases are documented in the US annually, with the disease’s geographic spread significantly increasing since 1995.

Among Missouri hunters, views on the vaccine vary. Generally, they seek assurances on its safety and efficacy. Familiarity with Lyme symptoms observed in acquaintances influences their opinions.

Insights from Experience

Conservationist Steven Rinella recalled contracting Lyme during a fishing expedition in New York, suffering prolonged symptoms necessitating intravenous antibiotics. This history makes Rinella willing to consider vaccination for his future well-being.

Jeremy Hollingshead noted his roommate’s long-term Lyme effects over a decade despite Lyme’s rarity among his circle. Meanwhile, Julian Barnes, influenced by a relative’s struggles, remains open to vaccination, contingent on thorough understanding.

Regulatory Path Forward

The new Lyme vaccine’s trials reported a 75% effectiveness rate in reducing cases. Despite missing one trial target, the companies proceeded with regulatory submissions. Uncertainty lingers amid shifts in vaccine approval processes under Health Secretary Robert F. Kennedy Jr., known for Lyme disease advocacy.

The FDA’s approval, potentially accompanied by Kennedy’s endorsement, might mitigate resistance within his support base. Kirzinger emphasized Kennedy’s influence, noting that supporters trust his health stance as much as personal physicians.

While some hunters remain undecided, JP Cummings chooses reliance on natural resilience yet stays curious about peer reactions as vaccine developments unfold.

KFF Health News conducts investigative journalism on health matters, serving as a key division within KFF.